Related Experiment Videos
[Lipid peroxidation processes in patients with schizophrenia]
Zhurnal Nevropatologii I Psikhiatrii Imeni S.S. Korsakova (Moscow, Russia : 1952)
|January 1, 1989
Summary
Lipid peroxidation (LP) was elevated in most schizophrenia patients before treatment and decreased during therapy. This reduction correlated with disease severity, suggesting LP as a potential biomarker.
Area of Science:
- Biochemistry
- Neuroscience
- Psychiatry
Context:
- Schizophrenia is a complex psychiatric disorder.
- Lipid peroxidation (LP) is a marker of oxidative stress.
- Psychotropic drug therapy is a standard treatment for schizophrenia.
Purpose:
- To investigate the course of lipid peroxidation (LP) in schizophrenic patients undergoing psychotropic drug therapy.
- To assess the relationship between LP levels and disease severity, duration, and negative symptoms.
Summary:
- Lipid peroxidation (LP), measured by pentane in expired air, was elevated in 80% of schizophrenia patients before therapy.
- LP levels decreased during treatment, reaching levels comparable to healthy controls in remission.
- LP exhibited 'leap-like' increases exceeding control levels, with their frequency and baseline elevation correlating with disease severity and duration.
Impact:
- Findings suggest that lipid peroxidation (LP) may serve as a biomarker for schizophrenia.
- Therapy-induced reduction in LP indicates a potential therapeutic target for managing oxidative stress in schizophrenia.
- Correlations between LP and clinical parameters highlight its relevance in understanding disease pathophysiology.